Pediatric Growth Hormone DeficiencySymptoms, Doctors, Treatments, Advances & More
Pediatric Growth Hormone Deficiency Overview
Learn About Pediatric Growth Hormone Deficiency
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Barrow Neuro-Endocrine Clinic
Kevin C. J. Yuen, MD, is a neuroendocrinologist and Medical Director of the Pituitary Program at Barrow Neurological Institute, specializing in the management of hypothalamic-pituitary disorders. He is double board-certified in Endocrinology and Internal Medicine by the American Board of Internal Medicine, and General Medical Council in the UK.Dr. Yuen's expertise includes clinical and research interest in the management of pituitary and adrenal disorders, particularly adults with growth hormone deficiency, acromegaly, hypogonadism, Cushing's disease and adrenal insufficiency. He also has a particular interest in neuroendocrine disorders in young adult cancer survivors and adults with traumatic brain injury. His research is devoted to new diagnostics and treatments of pituitary disorders.Dr. Yuen completed his medical degree from the University of Sheffield. He completed his residency in internal medicine at the University of Southampton, UK, clinical and research fellowship in Endocrinology at the University of Cambridge, UK, and clinical and research instructor at Oregon Health and Science University, Portland OR. Dr. Yuen is active in international collaborative studies and has published numerous peer-reviewed medical articles.My mission, along with the Dignity Health Medical Group, is to focus on innovative clinical care and the pursuit of excellence through scholarly activities. This allows me to provide patients with state-of-the-art patient services and exceptional patient experiences. Dr. Yuen is rated as an Elite provider by MediFind in the treatment of Pediatric Growth Hormone Deficiency. He is also highly rated in 42 other conditions, according to our data. His clinical expertise encompasses Growth Hormone Deficiency (GHD), Hypopituitarism, Sheehan Syndrome, Hormone Replacement Therapy (HRT), and Endoscopic Transnasal Transsphenoidal Surgery. Dr. Yuen is board certified in Internal Medicine (Sub: Endocrinology, Diabetes & Met and Internal Medicine. Dr. Yuen is currently accepting new patients.
Nemours Children's Health, Philadelphia
Judith Ross is a Medical Genetics provider practicing medicine in Philadelphia, Pennsylvania. She has been practicing medicine for over 12 years. Dr. Ross is rated as an Elite provider by MediFind in the treatment of Pediatric Growth Hormone Deficiency. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Klinefelter Syndrome, Turner Syndrome, Idiopathic Short Stature (ISS), Intersex, and Hormone Replacement Therapy (HRT). Dr. Ross is board certified in American Board Of Pediatrics.
Stanford Hospital And Clinics
Aimee Shu is an Endocrinologist practicing medicine in Stanford, California. Dr. Shu is rated as an Elite provider by MediFind in the treatment of Pediatric Growth Hormone Deficiency. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Pediatric Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Hypoparathyroidism, Postmenopausal Osteoporosis, and Hormone Replacement Therapy (HRT).
Summary: The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to respond to therapy with daily oral LUM-201.
Summary: Since 1985, growth hormone deficiency (GHD) in children has been the first condition treated with daily injections of recombinant human growth hormone. Noncompliance with daily growth hormone (GH) therapy is common. Several long-acting growth hormone (LAGH) treatments have recently become available for prescription in France after pivotal phase III trials demonstrated the non-inferiority of these ...

